Filing Flows › Atrium Therapeutics (RNA) › Q1 2026
Atrium Therapeutics (RNA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Atrium Therapeutics (RNA) reported revenue of $19.6M for the first quarter 2026 (Q1 2026), up 12-fold from a year earlier. Operating margin was -88.0%, net loss $16.6M (84.7% of revenue).
Atrium Therapeutics, Q1 2026: revenue $19.6M (12× year over year), operating margin -88.0%, net loss $16.6M, operating cash flow −$31.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.6M | — | 12× |
| Operating profit | −$17.3M | — | — |
| Net earnings | −$16.6M | — | — |
| Operating cash flow | −$31.1M | — | — |
What changed
Revenue was $19.6M in Q1 2026, up 1148% year over year.
Operating costs exceeded revenue by $17.3M, an operating margin of -88.0%. Total costs grew 309% against revenue growth of 1148%. The fastest-growing cost line was General & admin (+870%). The quarter ended with a net loss of $16.6M.
Operating cash flow was −$31.1M. Non-cash charges added back $151K of depreciation and $12.2M of share-based compensation. Working capital and other items used $26.9M. Capital expenditures of $2.1M exceeded it, leaving free cash flow of −$33.2M.
Questions
What was Atrium Therapeutics' revenue in the first quarter 2026?
Atrium Therapeutics (RNA) reported revenue of $19.6M for the first quarter 2026 (Q1 2026), up 12-fold from a year earlier.
Was Atrium Therapeutics profitable in the first quarter 2026?
Operating loss was $17.3M (-88.0% of revenue) and net loss $16.6M.